Courtney DiNardo Selected Research

Primary Myelofibrosis (Myelosclerosis)

2/2017	Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.
1/2017	BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Courtney DiNardo Research Topics

Disease

24	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 11/2016
16	Neoplasms (Cancer) 01/2022 - 01/2015
8	Leukemia 01/2022 - 01/2015
4	Philadelphia Chromosome 01/2022 - 11/2015
4	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022 - 12/2017
4	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2021 - 10/2017
3	Chromosome Aberrations (Chromosome Abnormalities) 01/2022 - 07/2015
3	Infections 01/2022 - 11/2015
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2021 - 01/2019
3	Residual Neoplasm 01/2021 - 01/2017
2	Thrombocytopenia (Thrombopenia) 01/2022 - 01/2018
2	Leukocytosis (Pleocytosis) 01/2022 - 01/2017
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2021 - 12/2017
2	Tumor Lysis Syndrome 01/2021 - 01/2020
2	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 01/2020
2	Hypertension (High Blood Pressure) 12/2020 - 11/2015
2	Cytokine Release Syndrome 01/2020 - 12/2017
2	Primary Myelofibrosis (Myelosclerosis) 02/2017 - 01/2017
2	Acute Promyelocytic Leukemia 01/2017 - 01/2015
1	Dyskeratosis Congenita (X-Linked Dyskeratosis Congenita) 03/2022
1	Fever of Unknown Origin 01/2022
1	Anemia 01/2022
1	COVID-19 01/2021
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Osteoporosis 12/2020
1	Metabolic Bone Diseases (Osteopenia) 12/2020
1	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 01/2020
1	Brain Diseases (Brain Disorder) 01/2020
1	Myocarditis (Carditis) 01/2020
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2019
1	Fibrosis (Cirrhosis) 07/2018
1	Blast Crisis (Blast Phase) 12/2017
1	Mucositis 10/2017
1	Pancreatitis 11/2015

Drug/Important Bio-Agent (IBA)

11	venetoclaxIBA 01/2022 - 01/2019
6	Tyrosine Kinase InhibitorsIBA 01/2022 - 11/2015
3	Decitabine FDA Link 01/2022 - 10/2017
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2017
2	c-Mer Tyrosine KinaseIBA 01/2022 - 01/2021
2	ibrutinibIBA 08/2021 - 01/2019
2	Phosphotransferases (Kinase)IBA 01/2021 - 01/2017
2	Protein Isoforms (Isoforms)IBA 01/2021 - 11/2016
2	Sorafenib (BAY 43-9006)FDA Link 11/2019 - 01/2019
2	ponatinibIBA 12/2017 - 11/2015
2	ruxolitinibIBA 02/2017 - 01/2017
2	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2017 - 01/2017
1	fms-Like Tyrosine Kinase 3IBA 01/2022
1	Core Binding Factors (Core-Binding Factor)IBA 01/2022
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2022
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022
1	CreatinineIBA 01/2022
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2022
1	gilteritinibIBA 12/2021
1	VaccinesIBA 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	isocitric acid (isocitrate)IBA 01/2021
1	Biological ProductsIBA 01/2021
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021
1	tyrosine receptor (receptor, tyrosine)IBA 01/2021
1	Oxidoreductases (Dehydrogenase)IBA 01/2021
1	cobimetinibIBA 01/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	Chimeric Antigen ReceptorsIBA 01/2020
1	CytokinesIBA 01/2020
1	midostaurinIBA 11/2019
1	NucleophosminIBA 01/2019
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2019
1	Indicators and Reagents (Reagents)IBA 07/2018
1	Hemoglobins (Hemoglobin)IBA 07/2018
1	enasidenibIBA 04/2018
1	Transaminases (Aminotransferases)IBA 01/2018
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2018
1	N 30IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	Messenger RNA (mRNA)IBA 01/2018
1	Inotuzumab OzogamicinIBA 01/2018
1	SteroidsIBA 12/2017
1	Dasatinib (BMS 354825)FDA Link 12/2017
1	blinatumomabIBA 12/2017
1	tocilizumab (atlizumab)FDA Link 12/2017
1	bosutinibIBA 12/2017
1	vosaroxinIBA 10/2017
1	Topoisomerase II InhibitorsIBA 10/2017
1	QuinolonesIBA 10/2017
1	Arsenic Trioxide (Trisenox)FDA Link 01/2017
1	Janus KinasesIBA 01/2017
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2017
1	Gemtuzumab (Mylotarg)FDA Link 01/2017
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2017
1	GlutaminaseIBA 11/2016
1	Glutamine (L-Glutamine)FDA Link 11/2016
1	IsoenzymesIBA 11/2016
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 11/2015
1	Vincristine (Oncovin)FDA LinkGeneric 11/2015

Therapy/Procedure

18	Therapeutics 01/2022 - 01/2015
11	Drug Therapy (Chemotherapy) 01/2022 - 11/2015
3	Induction Chemotherapy 11/2019 - 01/2017
1	Transplantation 03/2022
1	Immunotherapy 01/2021
1	Consolidation Chemotherapy 01/2018